Technical Analysis for AZN - Astrazeneca PLC

Grade Last Price % Change Price Change
grade F 52.61 0.02% 0.01
AZN closed up 0.02 percent on Friday, November 27, 2020, on 2.96 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical AZN trend table...

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
200 DMA Support Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Cup with Handle Other 0.02%
Stochastic Reached Oversold Weakness 0.02%
Down 3 Days in a Row Weakness 0.02%
Gapped Down Weakness 0.02%
Oversold Stochastic Weakness 0.02%
Fell Below 20 DMA Bearish -1.79%
Older End-of-Day Signals for AZN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics; and a strategic collaboration with FibroGen, Inc. to develop and commercialize FG-4592, a compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.
Cancer Drugs Antibodies Monoclonal Antibodies Neuroscience Infection Breast Cancer Schizophrenia Coronavirus Psychoactive Drugs Asthma Chronic Kidney Disease Heart Failure Hypertension Anemia Astrazeneca End Stage Renal Disease Autoimmune And Inflammatory Diseases Pulmonology Angina Bipolar Disorder Chronic Obstructive Pulmonary Diseases Respiratory Disease Chronic Condition Major Depressive Disorders Södertälje Municipality Bipolar Disorders Ironwood Pharmaceuticals

Is AZN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 64.94
52 Week Low 36.15
Average Volume 4,992,276
200-Day Moving Average 52.15
50-Day Moving Average 54.07
20-Day Moving Average 54.46
10-Day Moving Average 54.54
Average True Range 1.34
ADX 16.46
+DI 23.84
-DI 39.61
Chandelier Exit (Long, 3 ATRs ) 54.05
Chandelier Exit (Short, 3 ATRs ) 53.82
Upper Bollinger Band 58.62
Lower Bollinger Band 50.29
Percent B (%b) 0.28
BandWidth 15.30
MACD Line -0.05
MACD Signal Line 0.29
MACD Histogram -0.3365
Fundamentals Value
Market Cap 138.08 Billion
Num Shares 2.62 Billion
EPS 0.95
Price-to-Earnings (P/E) Ratio 55.38
Price-to-Sales 5.61
Price-to-Book 11.90
PEG Ratio 1.28
Dividend 1.40
Dividend Yield 2.66%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 54.61
Resistance 3 (R3) 54.44 53.60 54.27
Resistance 2 (R2) 53.60 53.10 53.69 54.16
Resistance 1 (R1) 53.11 52.78 53.36 53.28 54.05
Pivot Point 52.27 52.27 52.40 52.36 52.27
Support 1 (S1) 51.78 51.77 52.03 51.95 51.17
Support 2 (S2) 50.94 51.45 51.03 51.06
Support 3 (S3) 50.45 50.94 50.95
Support 4 (S4) 50.62